University of Edinburgh spinout Trogenix has announced that the first patient has been dosed in a Phase I/II clinical trial to evaluate its novel gene therapy platform targeting brain cancer.
A single dose of an innovative gene therapy could eliminate hard-to-treat brain tumours and prevent them from coming back, according to a pre-clinical trial in mice, reported in Nature.
A new contract manufacturing facility at the University of Edinburgh has received Medicines and Healthcare products Regulatory Agency (MHRA) approval to import and manufacture Investigational Medicinal Products for use in human clinical trials.
A longstanding collaboration between the University of Edinburgh and biomanufacturing company FUJIFILM Biotechnologies has led to the launch of a new protein purification platform designed to make the production of biological medicines faster and more straightforward.
Biopharmaceutical spinout Resolution Therapeutics has announced the first patient has been dosed and safety cleared in the Phase I/II EMERALD study of its novel therapy for end-stage liver disease.
New University of Edinburgh spinout Forth Therapeutics (Forth Tx) has launched with a precision therapeutics platform focused on tackling fibrosis across multiple organ systems.
Global biopharmaceutical company Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) and viral vector manufacturing company OXB have announced the start of a Phase I/II trial of a novel gene therapy that could improve outcomes for people with cystic fibrosis.
Gene control company Concinnity Genetics, recently spun out of the University of Edinburgh, has raised £3 million in an oversubscribed seed funding round that included Old College Capital (OCC) - the University of Edinburgh’s in-house venture investment fund.
What’s your next challenge? Spin in, spin out or start up?
